Focus Stocks
HSBC Close to the 200 Day
Published on Thursday, 09 February 2012 06:24 Written by TradersHuddle Wire
New York, February 9th (TradersHuddle.com) - Shares of HSBC Holdings plc (NYSE:HBC) traded at $44.95 close to its 200 day moving average currently set at $44.16. HSBC's price action is just above this key support level, and it will certainly raise traders attention, as a possible trading opportunity.
HSBC Holdings plc (NYSE:HBC) is the holding company for the HSBC Group. The Financial firm provides a variety of international banking and financial services, including retail and corporate banking, trade, trusteeship, securities, custody, capital markets, treasury, private and investment banking, and insurance. The Group is headquartered in London and operates worldwide. The firm is the largest lender in Europe and one of the largest banking institutions worldwide, with the most emerging markets exposure.
Latest price action range, defined by a peaks and troughs algorithm places calculated support at $36.67 and calculated resistance at $44.40. These levels will certainly be watched by traders, as they provide insight into the latest price dynamics defined by HSBC stock.
Traders wanting to establish a position on HSBC will be looking at the price action for evidence of buying near the 200 day moving average, and opening a position as close as possible to this important level. Also traders will be looking at the latest price action, via the stocks current range previously defined for insights of other key levels that might affect their upside or downside.
Related Articles
- Is HSBC Reversing?
- HSBC Appoints Michael Cummins Head of U.S. Payments and Cash Management
- HSBC Is Dipping Below Support
- HSBC Is in a Well Defined Range
- Is HSBC Waiting for a Break Out?
- Trading Idea: - Is HSBC close to Resistance?
- Close to the 50 Day Moving Average: HSBC
- Stock Futures Lower amid Euro Zone Jitters. Stocks to Watch: AAPL, BAC, DNDN, EA, FCX, HBC, DIS, WYNN
- HSBC Is Near Resistance
- HSBC Broke Resistance
Related Partner Headlines
- HSBC Beats Estimates with 26% Profit Rise - Benzinga
- HSBC Receives $914 Million for General Insurance Business - Benzinga
- UPDATE: HSBC sells general insurance business for $914 mln - Benzinga
- HSBC Agrees To Sell General Insurance Business For $914M - Benzinga
- HSBC Down 4.6% Following 2011 Earnings Announcement - Benzinga
- UPDATE: HSBC 2011 Profit Surges 28%, Declares Dividend - Benzinga
- RBS Takes a Hit on Greek Debt - Benzinga
- HSBC Fined for Selling 5-Year Bonds to 83-Year-Olds - TheStreet.com
- Toyota, HSBC, Sina: Hot Trends - TheStreet.com
- How to Sell Overseas, No Matter Company Size - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Coming Week: Top Nine Earnings on Deck - TheStreet.com -
Something's Not Right in the Video-Game Space - TheStreet.com -
For Ambitious Students, Entrepreneurship Can Be a Big Win - TheStreet.com -
Stock Futures Rise on Eurobond Talk - TheStreet.com -
You Can Let Your Guard Down: Ask Noah - TheStreet.com -
Apple Strengthens Its Supply Chain - TheStreet.com -
NYSE Is Winning the IPO Listing War - TheStreet.com -
Toyota Is Back as May Sales Continue Auto Industry Recovery - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis -
SunOpta Enters Into Agreement to Divest Its Canadian Based Natural Health Products Business -
PC Connection, Inc. (PCCC) To Present at The SeeThruEquity First Annual Small Cap Investor Conference on Tuesday, June 5, 2012 -
Aeroflex Announces Amendment to Credit Agreement -
Alliance Data to Participate at Upcoming Investor Conferences -
PCA3 Test Featured at American Urological Association Meeting -
MOCON Announces Quarterly Dividend -
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus









